Cytosorbents Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Cytosorbents Crp
CTSO Stock  USD 1.13  0.03  2.73%   
Cytosorbents Crp financial statements provide useful quarterly and yearly information to potential Cytosorbents Crp investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Cytosorbents Crp financial statements helps investors assess Cytosorbents Crp's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Cytosorbents Crp's valuation are summarized below:
Gross Profit
23.7 M
Profit Margin
(0.49)
Market Capitalization
68.6 M
Enterprise Value Revenue
2.685
Revenue
37.7 M
We have found one hundred twenty available fundamental signals for Cytosorbents Crp, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to validate Cytosorbents Crp's prevailing fundamentals against the trend between 2010 and 2025 to make sure the company can sustain itself down the road. As of the 18th of March 2025, Enterprise Value is likely to grow to about 93.7 M, while Market Cap is likely to drop about 42.4 M.

Cytosorbents Crp Total Revenue

43.89 Million

Check Cytosorbents Crp financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cytosorbents Crp's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.4 M, Interest Expense of 135 K or Selling General Administrative of 45.7 M, as well as many indicators such as Price To Sales Ratio of 1.49, Dividend Yield of 0.002 or PTB Ratio of 2.01. Cytosorbents financial statements analysis is a perfect complement when working with Cytosorbents Crp Valuation or Volatility modules.
  
Check out the analysis of Cytosorbents Crp Correlation against competitors.
To learn how to invest in Cytosorbents Stock, please use our How to Invest in Cytosorbents Crp guide.

Cytosorbents Crp Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets64.3 M61.2 M34 M
Slightly volatile
Short and Long Term Debt Total22.1 M21.1 M9.3 M
Slightly volatile
Total Current Liabilities17.6 M16.7 M7.9 M
Slightly volatile
Cash13.2 M16.3 M16.3 M
Slightly volatile
Common Stock Total Equity51.6 K39.3 K67.9 K
Slightly volatile
Common Stock Shares Outstanding53.9 M51.4 M28.4 M
Slightly volatile
Liabilities And Stockholders Equity64.3 M61.2 M34 M
Slightly volatile
Total Liabilities36.2 M34.5 M17 M
Slightly volatile
Property Plant And Equipment Gross30.4 M28.9 M8.6 M
Slightly volatile
Total Current Assets17.6 M29.6 M22.3 M
Slightly volatile
Other Current Liabilities7.8 M7.4 M4.1 M
Slightly volatile
Property Plant And Equipment Net26.7 M25.4 M8 M
Slightly volatile
Non Current Assets Total33.3 M31.7 M10.9 M
Slightly volatile
Cash And Short Term Investments14.1 M16.3 M16.6 M
Slightly volatile
Non Current Liabilities Total18.6 M17.8 M9.2 M
Slightly volatile
Other Stockholder Equity368.5 M351 M193.6 M
Slightly volatile
Common Stock53.5 K48.8 K69.3 K
Slightly volatile
Accounts Payable4.6 M4.4 M1.9 M
Slightly volatile
Non Currrent Assets Other1.2 M1.8 M1.4 M
Slightly volatile
Other Current Assets1.2 M2.1 M1.4 M
Slightly volatile
Good Will5.1 M4.9 M2.4 M
Slightly volatile
Intangible Assets4.7 M4.5 M2.4 M
Slightly volatile
Other Assets1.1 M2 M1.2 M
Slightly volatile
Property Plant Equipment13 M12.4 M4.8 M
Slightly volatile
Net Receivables7.3 M7 M3.1 M
Slightly volatile
Inventory4.4 M4.2 M2 M
Slightly volatile
Short Term Debt3.5 M3.3 M1.4 M
Slightly volatile
Net Tangible Assets23.3 M40.7 M19.6 M
Slightly volatile
Current Deferred Revenue968.5 K1.6 M771 K
Slightly volatile
Capital Surpluse215.6 M330.1 M188.2 M
Slightly volatile
Short and Long Term Debt1.8 M2.9 M1.7 M
Slightly volatile
Long Term Debt Total9 M15.4 M8.4 M
Slightly volatile
Long Term Investments133.2 K144.8 K118.2 K
Slightly volatile
Net Invested Capital43.4 M32.6 M30.9 M
Slightly volatile
Net Working Capital12.2 M12.8 M19.9 M
Pretty Stable
Capital Stock45.6 K62.4 K38.2 K
Slightly volatile
Capital Lease Obligations9.3 M15.3 M4.8 M
Slightly volatile

Cytosorbents Crp Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization2.4 M2.3 M714.1 K
Slightly volatile
Selling General Administrative45.7 M43.6 M20.7 M
Slightly volatile
Total Revenue43.9 M41.8 M19 M
Slightly volatile
Other Operating Expenses81.6 M77.7 M34.9 M
Slightly volatile
Cost Of Revenue16.9 M16.1 M7.1 M
Slightly volatile
Total Operating Expenses64.7 M61.6 M27.8 M
Slightly volatile
Research Development19 M18.1 M8.5 M
Slightly volatile
Preferred Stock And Other Adjustments287.1 K302.2 K845.5 K
Slightly volatile
Non Recurring1.2 M1.5 M1.2 M
Slightly volatile
Interest Income113.7 K119.7 K509.6 K
Pretty Stable
Reconciled Depreciation2.4 M2.3 M777.8 K
Slightly volatile

Cytosorbents Crp Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow28.8 M27.4 M17.3 M
Slightly volatile
Depreciation2.4 M2.3 M714.1 K
Slightly volatile
Total Cash From Financing Activities10.1 M16.6 M12.4 M
Slightly volatile
End Period Cash Flow13.4 M18 M16.7 M
Slightly volatile
Stock Based Compensation3.1 M4.3 M2.6 M
Slightly volatile
Change To Netincome4.3 M8.1 M3.7 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.491.57214
Slightly volatile
Dividend Yield0.0020.00220.0105
Slightly volatile
Days Sales Outstanding88.5669.9485.8743
Slightly volatile
Average Payables2.6 M2.5 M1.6 M
Slightly volatile
Stock Based Compensation To Revenue0.20.120.2064
Slightly volatile
Capex To Depreciation0.390.422.9968
Very volatile
EV To Sales1.621.7213
Slightly volatile
Inventory Turnover3.233.413.6998
Pretty Stable
Days Of Inventory On Hand1051111.8 K
Slightly volatile
Payables Turnover2.913.33.3428
Slightly volatile
Sales General And Administrative To Revenue1.141.27.4948
Slightly volatile
Average Inventory3.4 M3.2 M1.9 M
Slightly volatile
Research And Ddevelopement To Revenue0.470.511.5631
Slightly volatile
Capex To Revenue0.02810.02960.2811
Slightly volatile
Cash Per Share0.350.360.492
Slightly volatile
Days Payables Outstanding1091142.8 K
Slightly volatile
Income Quality0.610.680.7439
Pretty Stable
Intangibles To Total Assets0.10.08440.0925
Slightly volatile
Current Ratio1.961.592.5426
Slightly volatile
Receivables Turnover4.35.45.0067
Slightly volatile
Capex Per Share0.03530.01890.0464
Pretty Stable
Average Receivables5.5 M5.3 M3 M
Slightly volatile
Revenue Per Share0.770.730.4767
Slightly volatile
Interest Debt Per Share0.50.480.285
Slightly volatile
Debt To Assets0.350.40.3339
Very volatile
Operating Cycle1721811.9 K
Slightly volatile
Days Of Payables Outstanding1091142.8 K
Slightly volatile
Ebt Per Ebit0.730.851.1313
Slightly volatile
Quick Ratio1.831.362.3325
Slightly volatile
Net Income Per E B T0.650.880.9181
Slightly volatile
Cash Ratio1.470.871.8218
Slightly volatile
Days Of Inventory Outstanding1051111.8 K
Slightly volatile
Days Of Sales Outstanding88.5669.9485.8743
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.880.941.0944
Very volatile
Fixed Asset Turnover1.411.485.704
Very volatile
Debt Ratio0.350.40.3339
Very volatile
Price Sales Ratio1.491.57214
Slightly volatile
Asset Turnover0.350.610.4485
Slightly volatile

Cytosorbents Crp Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap42.4 M44.6 M110.8 M
Pretty Stable
Enterprise Value93.7 M48.4 M105.6 M
Pretty Stable

Cytosorbents Fundamental Market Drivers

Forward Price Earnings7.734
Cash And Short Term Investments14.1 M

Cytosorbents Upcoming Events

14th of March 2024
Upcoming Quarterly Report
View
7th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Cytosorbents Crp Financial Statements

Cytosorbents Crp investors utilize fundamental indicators, such as revenue or net income, to predict how Cytosorbents Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue1.6 M968.5 K
Total Revenue41.8 M43.9 M
Cost Of Revenue16.1 M16.9 M
Stock Based Compensation To Revenue 0.12  0.20 
Sales General And Administrative To Revenue 1.20  1.14 
Research And Ddevelopement To Revenue 0.50  0.47 
Capex To Revenue 0.03  0.03 
Revenue Per Share 0.73  0.77 
Ebit Per Revenue(0.77)(0.81)
When determining whether Cytosorbents Crp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cytosorbents Crp's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cytosorbents Crp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cytosorbents Crp Stock:
How To Invest In Cytosorbents
Details
Is Cytosorbents Stock a good investment?
Details
What is Cytosorbents Crp's Net Worth?
Details
Largest Health Care Equipment & Supplies Companies
View
Largest Health Care Equipment & Services Companies
View
Check out the analysis of Cytosorbents Crp Correlation against competitors.
To learn how to invest in Cytosorbents Stock, please use our How to Invest in Cytosorbents Crp guide.
You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytosorbents Crp. If investors know Cytosorbents will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytosorbents Crp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.36)
Revenue Per Share
0.72
Quarterly Revenue Growth
0.066
Return On Assets
(0.28)
Return On Equity
(1.19)
The market value of Cytosorbents Crp is measured differently than its book value, which is the value of Cytosorbents that is recorded on the company's balance sheet. Investors also form their own opinion of Cytosorbents Crp's value that differs from its market value or its book value, called intrinsic value, which is Cytosorbents Crp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytosorbents Crp's market value can be influenced by many factors that don't directly affect Cytosorbents Crp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Cytosorbents Crp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytosorbents Crp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytosorbents Crp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY